

Colorado COVID-19 Vaccine Screening and Administration Form



Please	e print nea	atly in	capital	letters	as sho	own in	the ex	xample	: Pleas	o ansu	or al	II aug	stions (as coi	mnlet	elv as									
E	<u>, , , , , , , , , , , , , , , , , , , </u>	M	Γ <u>΄</u> Τ		Ε	1	2	3	possi	ble.			ink to				In	e adn this d				cord	is on the	rever	se side
Dleas	se comp	lete	AII :	the ir	oform	ation	hel	OW 39	s accili	rately	/ 25	noss	ible	If v	ב ווכ	re co	mpl	otir	na tl	nis f	orr	n for	Vour	mino	r
	I, do no																								, 1
Patie	nt/Child	Last I	Name											Pati	ent/	Child	First	Nan	ne						<u>M.I.</u>
Date of Birth Age (years) Age (months) Patient/Representative Daytime Phone													e Numb	er											
			\rfloor/\lvert]-[-[
M If und	M er 18 year	D D			Y Y	′ Y							Par	rent l	_ast N	lame					. –				
	please	, <u></u>		Jerian																					
Addr	ess			-						_	•					-			•	-	Ap	t. Nu	mber		
, au																									
City														Stat											
													<u> </u>] [Ĭ	
Zip C	ode			E-n	nail Ac	ddres	 S							-									J L		
Gender Identity F M Transgender Female/Feminine Transgender Male/Masculine Non-Binary Un-specified Decline to Provide												wide													
	ou Hispa								that app		350110		200771103	Jeann			Jiliai y			эрсс			Decime		71140
	s No								n/Alask		ive	∏Bla	ack, Af	rican	Ame	rican		ſ	□ot	her		□De	cline to	Provid	e
						Asi	ian					☐ Na	tive Ha	awaii	an/Pa	acific I	slande	er [□w	hite					
Health Insurance (OPTIONAL-INSURANCE NOT REQUIRED FOR VACCINATION) Insurance Policy Number																									
Ме	dicaid	Medi	care T	Kaise	er Perm	anent	e Uni	ted He	althcare 7	e Oth	ner Pr Г	ivate T	No	Insur	ance 1										
f you l	nave alread	ly rece	ived yo	ur Prim	nary Dos	se(s) of	a COV	 ′ID-19 v	accine, p	lease t	ell us	which	vaccine	e(s) yo	u rece	eived a	nd the	date(s) of	vacci	natio	n.	-		
ose(s)	received:	Dose 1	1: Vacci	ine Brar	nd		Vacci	ination	Date	/_	/		_ Dos	e 2: V	accine	e Branc			_ Vac	cinati	on D	ate	/_	/_	
	nave alread																								nation.
Additio	onal Dose r	eceive	d for H	igh Risk	Condit	ions : \	Vaccine	e Brand		Va	ccina	tion Da	ate	/_		/	_								
Booste	r Dose: Va	cine B	rand		Vacc	ination	n Date				Ada	litiona	l Booste	er Dos	e: Vac	cine B	and			Vacci	natio	n Date	·	/	/
Healt	h Screening	Questi	ions																				Yes	No	Don't Know
1.	Are you o	r your	child si	ck toda	y or hav	e a fev	er?		_		_				_			_	_	_	_				
2.	Have you or your child had an allergic reaction to polysorbate, polyethylene glycol, or a previous dose of COVID-19 vaccine?																								
3.	Have you or your child ever had a serious allergic reaction (anaphylaxis) to another vaccine or any injectable medication?																								
4.	Have you or your child had severe allergic reaction (anaphylaxis) to foods, pets, venom, environmental or oral medications?																								
5.	5. Do you or your child have a bleeding disorder, are on long-term aspirin therapy, or take other blood thinners?																								
6.	6. Have you or your child ever had Guillain-Barré Syndrome (a type of temporary severe muscle weakness) after receiving a vaccine?																								
7.	7. Have you received any dermal fillers (Juvaderm®, Restylane®, etc.)? (only applies to mRNA vaccines)																								
8.	B. Do you have a history of blood clots or have risk factors for developing blood clots? (Janssen vaccine only, applies to females ages 18-49)																								
9.	Do you or your child have a history of myocarditis or pericarditis? (Especially males ages 12-29 years after receiving a dose of mRNA vaccine)																								
10.	Do you or your child have a history of heparin-induced thrombocytopenia (HIT)? Do you or your child have a history of Multisystem Inflammatory Syndrome known as MIS-C (in children) or MIS-A (in adults) after a COVID-19																								
11.	Do you or infection		hild ha	ve a his	tory of I	Multisys	stem Ir	nflamma	atory Syn	drome k	known	as MIS	S-C (in c	hildre	n) or	MIS-A (in adul	ts) af	ter a	COVIE)-19				
12.	Are you o	r your o	child im	munoco	omprom	ised? (S	ee add	litional	dose sect	ion on r	ext p	age)													

05/20/2022 Continued on Next Page

Patient/Child Last Name		Patient/Child First Na	me M.I.				
Date of Birth /]/ []]	Age (years) Age (mo	Primary Dose: 1 2 3 Booster Dose: 1 2*				
M M D D Authorization to Administer COVID-19	Y Y Y Y						
I have read or had explained to me the Fact Sheet for Recipients and Caregivers for the use of the COVID-19 vaccine and understand the benefits and risks to me or my child of receiving this vaccine. I have had a chance to ask questions, which were answered to my satisfaction. I hereby release this provider, its							
employees and its volunteers from any liabi	, ,	occur from the administra	tion of this vaccine.				
Signature of Patient/Parent/Legal Guardia Medical Durable Power of Attorney:							
STO	P: DO NOT WRITE BELOV	W THIS LINE-FOR CLIN	IIC STAFF ONLY				
COVID/VFC PIN Provider T	/pe Clinic Name		Provider Name				
Private							
Brand Name	I I I I I I I I I I I I I I I I I I I	fizer (Orange Cap) (ages 5 - 11 years)	Site Date Administered				
	(age 12 years +) Moderna (age 18 years +) 0.5 ml	Pediatric Primary and 0.2 ml Booster Dose 0.2 ml	LD LT M M M D D V Y Y Y Y				
Lot Number	(age 18 years +)	(ages 6 mo 4 years) Pediatric Primary	Administered by:				
	Pfizer 0.3 ml M	Noderna (ages 6 mo 5 years)	Name Title				
		Pediatric Primary Dose 0.25 ml					

For vaccine administration guidance, including: timing, dosing, site selection, needle length and gauge, and administration procedures, please reference your standing orders or the CDC's Interim Clinical Considerations".

https://covid19.colorado.gov/vaccine-providers

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

https://www.immunize.org/covid-19/

*Additional guidance from the FDA for 2nd booster dose is as follows:

- A second booster dose of either the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to
 individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19
 vaccine.
- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromising conditions at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
- A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.

*Additional Guidance for J &J Vaccine use:

- Assess persons 18 years of age and older for vaccination with Janssen COVID_19 Vaccine based on the following criteria:
 - mRNA COVID-19 Vaccines are preferred over Janssen COVID-19 Vaccine for primary series and booster vaccination
 - Inform all persons receiving a Janssen vaccine of the risks and symptoms of thrombosis with thrombocytopenia syndrome (TTS) in the 3 weeks after vaccination as was as the need to seek immediate care should symptoms develop.
- Janssen COVID-19 Vaccine may be offered in some situations:
 - · A true contraindication to mRNA vaccines (severe allergic reaction to a previous dose or a component of the vaccine
 - The person would otherwise remain unvaccinated for COVID-19 due to limited access to mRNA vaccine
 - The person wants to receive the Janssen COVID-19 vaccine despite the safety concerns identified